XML 54 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments
 9 Months Ended
Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]  
Financial Instruments
The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:
(In millions)As of September 30, 2020As of December 31, 2019
Commercial paper$649.2 $384.4 
Overnight reverse repurchase agreements465.4 368.8 
Money market funds270.2 1,628.5 
Short-term debt securities185.5 159.4 
Total$1,570.3 $2,541.1 
The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.
Our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities:
As of September 30, 2020
(In millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
Corporate debt securities:
Current$963.5 $1.4 $(0.1)$964.8 
Non-current475.9 3.2 (0.1)479.0 
Government securities:
Current389.4 0.2 — 389.6 
Non-current376.4 1.4 — 377.8 
Mortgage and other asset backed securities:
Current0.6 — — 0.6 
Non-current152.6 0.6 (0.2)153.0 
Total marketable debt securities$2,358.4 $6.8 $(0.4)$2,364.8 
Marketable equity securities, non-current$851.7 $63.6 $(46.8)$868.5 
As of December 31, 2019
(In millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
Corporate debt securities:
Current$1,057.2 $1.0 $— $1,058.2 
Non-current633.9 3.0 — 636.9 
Government securities:
Current502.9 0.4 — 503.3 
Non-current510.1 0.8 (0.3)510.6 
Mortgage and other asset backed securities:
Current0.7 — — 0.7 
Non-current260.2 0.8 (0.4)260.6 
Total marketable debt securities$2,965.0 $6.0 $(0.7)$2,970.3 
Marketable equity securities, non-current$218.4 $132.1 $(13.0)$337.5 
Summary of Contractual Maturities: Available-for-Sale Debt Securities
The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:
 As of September 30, 2020As of December 31, 2019
(In millions)Estimated
Fair Value		Amortized
Cost		Estimated
Fair Value		Amortized
Cost
Due in one year or less$1,355.0 $1,353.4 $1,562.2 $1,560.8 
Due after one year through five years902.2 897.9 1,234.5 1,230.4 
Due after five years107.6 107.1 173.6 173.8 
Total marketable debt securities$2,364.8 $2,358.4 $2,970.3 $2,965.0 
The average maturity of our marketable debt securities available-for-sale as of September 30, 2020 and December 31, 2019, was approximately 12 months and 14 months, respectively.
Proceeds from Marketable Debt Securities
The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
 For the Three Months Ended September 30,For the Nine Months Ended September 30,
(In millions)2020201920202019
Proceeds from maturities and sales$1,360.9 $611.8 $5,240.7 $3,867.6 
Realized gains1.0 0.7 12.8 2.3 
Realized losses(0.9)(0.1)(25.2)(0.7)
Strategic Investments
As of September 30, 2020 and December 31, 2019, our strategic investment portfolio was comprised of investments totaling $925.1 million and $393.9 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets.
Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in Note 7, Fair Value Measurements, to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.
The increase in our strategic investment portfolio for the three and nine months ended September 30, 2020, was primarily due to our purchases of Denali and Sangamo common stock, as discussed below.
Denali Therapeutics Inc.
In August 2020 we entered into a collaboration and license agreement with Denali. As part of this collaboration we purchased approximately 13 million shares of Denali common stock in September 2020. This investment is classified as a Level 2 marketable equity security due to certain holding period restrictions and is remeasured each reporting period and carried at fair value. The effects of certain holding period restrictions on the investment are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Denali's common stock and a dividend yield of zero based upon the fact that Denali and similar companies generally have not historically granted cash dividends.
For additional information on our collaboration agreements with Denali, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements.
Sangamo Therapeutics, Inc.
In February 2020 we entered into a collaboration and license agreement with Sangamo. In connection with the closing of this transaction in April 2020 we purchased approximately 24 million shares of Sangamo common stock. This equity method investment will be remeasured each reporting period and carried at fair value due to our election of the fair value option. The effects of certain holding period restrictions on the investment are estimated
using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk free-interest rate to match the remaining term of the restrictions on our investment in Sangamo’s common stock and a dividend yield of zero based upon the fact that Sangamo and similar companies generally have not historically granted cash dividends.
For additional information on our collaboration agreement with Sangamo, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements.